Alimera Sciences
-
Upload
healthegy -
Category
Healthcare
-
view
520 -
download
0
Transcript of Alimera Sciences
![Page 1: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/1.jpg)
OIS Presentation
November 11, 2015
![Page 2: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/2.jpg)
ILUVIEN: Revolutionizing DME Treatment
![Page 3: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/3.jpg)
3
The Only DME Treatment of its Kind
Proven to last 36 months (12x
longer than next comparable long-
acting product)
Continuous drug delivery
eliminates the inconsistent
treatment of other more frequently
dosed options
Long term efficacy with a single
injection is patient friendly
Sustained, Multi-Year Approach to
Diabetic Macular Edema
![Page 4: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/4.jpg)
4
Debilitating, Permanent Effects of DME
• Primary cause of vision loss in diabetic
patients
• Leaky blood vessels in the macula cause
the retina to swell
• Causes blurred vision in early stage, over
long term may cause cumulative damage
Photo courtesy of Marinel Casiano CRA and Sanford Chen MD
of Orange County Retina.
![Page 5: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/5.jpg)
5
DME Patients Need More
BCVA 20/20,
15.0%
BCVA 20/40,
31.6%
BCVA 20/60
24.3%
BCVA 20/80
16.4%
BCVA 20/100
12.6%
Source: ASI MR June 2014
~55% of patients
end up 20/60
or worse
Based on Research with MD’s,
BCVA Levels Long Term
(2+ Years) That Their Patients
Achieve
![Page 6: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/6.jpg)
6
Visual Impact
![Page 7: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/7.jpg)
7
ILUVIEN Consistently Delivers
Months
ILU
VIE
N P
atients
With Im
pro
vem
ent in
BC
VA
Fro
m
Base
line
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
0 3 6 9 12 15 18 21 24 27 30 33 36
≥ 1 Letter ≥ 1 Line ≥ 2 Line ≥ 3 Line
Please see ILUVIEN’s Full Prescribing information at www.ILUVIEN.com for important safety information. Data shown from FAME Study.
![Page 8: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/8.jpg)
What are the Doctors and Patients Saying?
![Page 9: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/9.jpg)
9
What are the Doctors and Patients Saying?
![Page 10: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/10.jpg)
Commercial Status
![Page 11: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/11.jpg)
11
ILUVIEN Launch Progress
France
SpainPortugal Italy
Ireland
U.K.
Germany Poland
Belgium
Denmark
Netherlands
Austria
Marketed Approved
CR
United States
CH
![Page 12: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/12.jpg)
12
License Deals
Canada
Australia
Israel
![Page 13: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/13.jpg)
13
Increasing Commercial Sales
Q32013
Q42013
Q12014
Q22014
Q32014
Q42014
Q12015
Q22015
Q32015
$758,000 $935,000
$2,100,000$2,201,000
$2,408,000
$1,741,000
$3,938,000
$5,776,000
$6,910,000
Driving Towards Profitability
![Page 14: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/14.jpg)
14
J Code Available in January
![Page 15: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/15.jpg)
15
Innovation in Ophthalmology
ILUVIEN Geographic Expansion
Patient Friendly
Products
Expanded ILUVIEN Platform
Making a difference in patients lives by
becoming a leading provider in retina care
![Page 16: Alimera Sciences](https://reader031.fdocuments.net/reader031/viewer/2022030304/587a67a21a28ab8a2a8b5bd5/html5/thumbnails/16.jpg)
OIS Presentation
November 11, 2015